APA (7th ed.) Citation

Busnadiego, I., Abela, I. A., Frey, P. M., Hofmaenner, D. A., Scheier, T. C., Schuepbach, R. A., . . . Hale, B. G. (2022). Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease. PLoS Biology, 20(7), 1. https://doi.org/10.1371/journal.pbio.3001709

Chicago Style (17th ed.) Citation

Busnadiego, Idoia, Irene A. Abela, Pascal M. Frey, Daniel A. Hofmaenner, Thomas C. Scheier, Reto A. Schuepbach, Philipp K. Buehler, Silvio D. Brugger, and Benjamin G. Hale. "Critically Ill COVID-19 Patients with Neutralizing Autoantibodies Against Type I Interferons Have Increased Risk of Herpesvirus Disease." PLoS Biology 20, no. 7 (2022): 1. https://doi.org/10.1371/journal.pbio.3001709.

MLA (9th ed.) Citation

Busnadiego, Idoia, et al. "Critically Ill COVID-19 Patients with Neutralizing Autoantibodies Against Type I Interferons Have Increased Risk of Herpesvirus Disease." PLoS Biology, vol. 20, no. 7, 2022, p. 1, https://doi.org/10.1371/journal.pbio.3001709.